| 61.95 -1.97 (-3.08%) | 10-16 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 80.56 |
1-year : | 87.19 |
| Resists | First : | 68.97 |
Second : | 74.65 |
| Pivot price | 63.51 |
|||
| Supports | First : | 59.79 | Second : | 49.74 |
| MAs | MA(5) : | 62.74 |
MA(20) : | 64.2 |
| MA(100) : | 74.47 |
MA(250) : | 68.69  |
|
| MACD | MACD : | -2.4 |
Signal : | -2.7 |
| %K %D | K(14,3) : | 44.2 |
D(3) : | 40.4 |
| RSI | RSI(14): 35.7 |
|||
| 52-week | High : | 88.3 | Low : | 54.29 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CYTK ] has closed above bottom band by 27.8%. Bollinger Bands are 33.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 63.97 - 64.34 | 64.34 - 64.67 |
| Low: | 60.85 - 61.25 | 61.25 - 61.6 |
| Close: | 61.38 - 62.01 | 62.01 - 62.58 |
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Sat, 17 Oct 2026
(CYTK) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Fri, 16 Oct 2026
William Blair Initiates Coverage on Cytokinetics With Outperform Rating - Yahoo Finance
Wed, 14 Oct 2026
Cytokinetics, Incorporated (CYTK) Stock Forecasts - Yahoo Finance
Tue, 13 Oct 2026
Cytokinetics, Incorporated (CYTK) stock price, news, quote and history - Yahoo Finance Singapore
Tue, 13 Oct 2026
A $1.42M proposed share sale at Cytokinetics (CYTK) draws on Robert Blum’s stock options. - Stock Titan
Tue, 13 Oct 2026
Cytokinetics (CYTK), What Is Behind The Fresh Attention? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 139 (M) |
| Shares Float | 138 (M) |
| Held by Insiders | 0.6 (%) |
| Held by Institutions | 125.8 (%) |
| Shares Short | 19,330 (K) |
| Shares Short P.Month | 17,440 (K) |
| EPS | -7.22 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -1.25 |
| Profit Margin | 0 % |
| Operating Margin | -626 % |
| Return on Assets (ttm) | -28.1 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | -57.1 % |
| Gross Profit (p.s.) | -2.43 |
| Sales Per Share | 0.48 |
| EBITDA (p.s.) | -5.01 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -555 (M) |
| Levered Free Cash Flow | -397 (M) |
| PE Ratio | -8.59 |
| PEG Ratio | 0 |
| Price to Book value | -49.57 |
| Price to Sales | 127.26 |
| Price to Cash Flow | -15.51 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|